Triple-Negative Breast Cancer EVs Modulate Growth and Migration of Normal Epithelial Lung Cells

被引:0
|
作者
Leone, Ilaria [1 ]
Santoro, Jessie [1 ]
Soricelli, Andrea [1 ]
Febbraro, Antonio [2 ]
Santoriello, Antonio [3 ]
Carrese, Barbara [1 ]
机构
[1] IRCCS SYNLAB SDN, Via E Gianturco, I-80143 Naples, Italy
[2] Casa Cura Cobellis, Oncol Unit, I-84078 Vallo Della Lucania, Italy
[3] Casa Cura Cobellis, Breast Unit, I-84078 Vallo Della Lucania, Italy
关键词
proliferation; triple-negative breast cancer; extracellular vesicles; intercellular communication; biomarkers; EXTRACELLULAR VESICLES; METASTASES;
D O I
10.3390/ijms25115864
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Breast cancer is the most common cancer amongst women worldwide. Recently, owing to screening programs and new technologies, the survival rate has increased significantly. Breast cancer can potentially develop metastases, and, despite them, lung metastases generally occur within five years of breast cancer diagnosis. In this study, the objective was to analyze the effect of breast cancer-derived EVs on a lung epithelial cell line. BEAS-2B cells were treated with extracellular vesicles (EVs) derived from triple-negative breast cancer cells (TNBCs), e.g., MDA-MB-231 and HS578T, separated using differential ultracentrifugation. We observed an increased growth, migration, and invasiveness of normal epithelial lung cells over time in the presence of TNBC EVs compared to the control. Therefore, these data suggest that EVs released by tumor cells contain biological molecules capable of influencing the pro-tumorigenic activity of normal cells. Exploring the role of EVs in oncology research and their potential cargo may be novel biomarkers for early cancer detection and further diagnosis.
引用
收藏
页数:13
相关论文
共 50 条
  • [41] PRKCQ promotes oncogenic growth and anoikis resistance of a subset of triple-negative breast cancer cells
    Jessica Byerly
    Gwyneth Halstead-Nussloch
    Koichi Ito
    Igor Katsyv
    Hanna Y. Irie
    Breast Cancer Research, 18
  • [42] Development of Triple-Negative Breast Cancer-Targeted Liposomes with MUC16 Binding Peptide Ligand in Triple-Negative Breast Cancer Cells
    Hagimori, Masayori
    Kato, Naoya
    Orimoto, Akira
    Suga, Tadaharu
    Kawakami, Shigeru
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2023, 112 (06) : 1740 - 1745
  • [43] Eribulin and Paclitaxel Differentially Alter Extracellular Vesicles and Their Cargo from Triple-Negative Breast Cancer Cells
    Pederson, Petra J.
    Liang, Huiyun
    Filonov, Daria
    Mooberry, Susan L.
    CANCERS, 2021, 13 (11)
  • [44] Synthesis and biological evaluation of chromone derivatives against triple-negative breast cancer cells
    Islam, Rajibul
    Yan, Mock Phooi
    Yen, Khor Poh
    Rasol, Nurulfazlina Edayah
    Meng, Chan Kok
    Wai, Lam Kok
    MEDICINAL CHEMISTRY RESEARCH, 2023, 32 (05) : 884 - 898
  • [45] Signaling pathways essential for triple-negative breast cancer stem-like cells
    Ehnnsen, Sidse
    Ditzel, Henrik J.
    STEM CELLS, 2021, 39 (02) : 133 - 143
  • [46] ANKHD1 contributes to the malignant phenotype of triple-negative breast cancer cells
    de Almeida, Bruna O.
    de Almeida, Larissa C.
    Costa-Lotufo, Leticia, V
    Machado-Neto, Joao A.
    CELL BIOLOGY INTERNATIONAL, 2022, 46 (09) : 1433 - 1446
  • [47] Reverse engineering of triple-negative breast cancer cells for targeted treatment
    Bluemel, Lena
    von Wahlde, Marie-Kristin
    Tio, Joke
    Kiesel, Ludwig
    Bernemann, Christof
    MATURITAS, 2018, 108 : 24 - 30
  • [48] Dasatinib is synergistic with cetuximab and cisplatin in triple-negative breast cancer cells
    Kim, Elizabeth M. H.
    Mueller, Kelly
    Gartner, Elaina
    Boerner, Julie
    JOURNAL OF SURGICAL RESEARCH, 2013, 185 (01) : 231 - 239
  • [49] In vitro therapeutic effects of abemaciclib on triple-negative breast cancer cells
    Ozman, Zeynep
    Guney Eskiler, Gamze
    Sekeroglu, Mehmet R.
    JOURNAL OF BIOCHEMICAL AND MOLECULAR TOXICOLOGY, 2021, 35 (09)
  • [50] Metabolic reprogramming in triple-negative breast cancer
    Wang, Zhanyu
    Jiang, Qianjin
    Dong, Chenfang
    CANCER BIOLOGY & MEDICINE, 2020, 17 (01) : 44 - 59